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Introduction: Adrenal myelolipoma (AML) is the second most common and invariably benign
primary adrenal neoplasm. Due to the variable proportion of fat and hematopoietic elements and
its often large size, it can cause differential diagnostic problems. Several reports confirmed the
utility of miRNAs in the diagnosis of tumors, but miRNA expression in AML has not yet
been investigated.
Materials and Methods: Next-generation sequencing (NGS) was performed on 30 formalin-fixed,
paraffin-embedded (FFPE) archived tissue samples [10 each of AML, adrenocortical adenoma (ACA),
and adrenocortical carcinoma (ACC)]. Validation was performed by real-time quantitative reverse
transcription polymerase chain reaction on a cohort containing 41 further FFPE samples (15 AML, 14
ACA, and 12 ACC samples). Circulating miRNA counterparts of significantly differentially expressed
tissue miRNAs were studied in 33 plasma samples (11 each of ACA, ACC, and AML).
Results: By NGS, 256 significantly differentially expressed miRNAs were discovered, and 8 of these
were chosen for validation. Significant overexpressionofhsa-miR-451a, hsa-miR-486-5p, hsa-miR-363-
3p, andhsa-miR-150-5pwas confirmed inAML relative toACAandACC.hsa-miR-184,hsa-miR-483-5p,
and hsa-miR-183-5p were significantly overexpressed in ACC relative to ACA but not to AML. Cir-
culating hsa-miR-451a and hsa-miR-363-3p were significantly overexpressed in AML, whereas cir-
culating hsa-miR-483-5p and hsa-miR-483-3p were only significantly overexpressed in ACC vs ACA.
Conclusions: We have found significantly differentially expressed miRNAs in AML and adreno-
cortical tumors. Circulating hsa-miR-451a might be a promising minimally invasive biomarker of
AML. The lack of significantly different expression of hsa-miR-483-3p and hsa-miR-483-5p between
AML and ACCmight limit their applicability as diagnostic miRNAmarkers for ACC. (J Clin Endocrinol
Metab 103: 3522–3530, 2018)
Adrenal neoplasms are common. Among adrenaltumors, adrenocortical adenomas (ACAs) are the
most frequent, constituting 60% to 70% of adrenal
incidentalomas. Adrenal myelolipoma (AML) is the
second most common primary adrenal tumor, repre-
senting 6% to 16% of all adrenal incidentalomas (1, 2).
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AML is an invariably benign tumor that is composed of
adipose tissue and extramedullary hematopoietic elements.
The pathogenesis of AML is unclear (3, 4). AMLs are often
large tumors with an average size of 10.2 cm at diagnosis
(3). On the other hand, adrenocortical carcinoma (ACC) is
an uncommon disease with an annual incidence of 0.5 to 2
per million (5–8) and a poor prognosis, with a 5-year
survival rate of ,15% in stage IV (9, 10).
Because of their large size, it might be occasionally
challenging to distinguish AML from other adrenal tu-
mors, especially ACCs, which also often present with a
large size (3, 8). Although the presence of macroscopic fat
is pathognomonic for AML, the variability in the content
of fat and hematopoietic elements in AML could lead to
an indeterminate appearance on imaging, and even in-
tense 18F-fluorodeoxyglucose uptake on positron emis-
sion tomography–CT due to the hemopoietic elements
was reported (11). Moreover, the age distribution of
AML is similar to that of ACC, with a peak incidence in
the fifth and sixth decades (9).
Mature miRNAs are short, 19- to 25-nucleotide-long
single-stranded noncoding RNA molecules that are in-
volved in the regulation of gene expression mostly at the
posttranscriptional level. miRNAs are expressed in a
tissue-specific fashion and secreted in body fluids (12).
Several studies have shown that miRNAs can be useful
biomarkers in different diseases, including various neo-
plasms. Recent studies, including ours, have reported
significant differences in tissue and circulating miRNA
expression of patients with ACA and ACC (13–17). To
our knowledge, the miRNA expression profile of adrenal
myelolipoma has not been investigated. With this in
mind, we hypothesized that miRNA profiling in AML
might lead to the identification of biomarkers that could
be used in challenging diagnostic situations.
Materials and Methods
Tissue collection and ethics approval
A total of 71 histologically proven formalin-fixed,
paraffin-embedded (FFPE) archived tissue samples were
used (Table 1). The discovery cohort contained 30 samples
(10 ACA, 10 ACC and 10 AML samples), and the in-
dependent validation cohort contained another 41 FFPE
samples (15 AML, 14 ACA, and 12 ACC samples). A total of
33 independent preoperative EDTA-anticoagulated plasma
samples from patients with histologically proven adrenal
tumors (11 samples each of ACA, ACC, and AML) were used
for the analysis of circulating miRNA. Preoperative bio-
chemical testing for hormonal evaluation involved basal
cortisol, ACTH, aldosterone, renin activity, dehydroepian-
drosterone sulfate, urinary catecholamines, and low-dose
dexamethasone test (cutoff: 1.8 mg/dL). The study was ap-
proved by the Ethical Committee of the Hungarian Health
Council. All experiments were performed in accordance with
relevant guidelines and regulations, and informed consent
was obtained from the involved patients.
Sample processing and RNA isolation
Total RNA was isolated from all the FFPE samples by the
RecoverAll Total Nucleic Acid Isolation Kit for FFPE (Thermo
Fisher Scientific, Waltham,MA). Total RNA from plasma was
isolated by the miRNeasy Serum/Plasma Kit (Qiagen GmbH,
Hilden, Germany). As a spike-in control for purification ef-
ficiency, 5 mL of 5 nM Syn-cel-miR-39 miScript miRNA
Mimic (Qiagen GmbH) was added before the addition of acid-
phenol/chloroform. Total RNA was stored at 280°C until
further processing.
miRNA expression profiling from tissue samples by
next-generation sequencing
The cDNA library was made from total RNA by the QIAseq
miRNA Library Kit (Qiagen GmbH) according to the in-
structions of the manufacturer. The library was prepared for
sequencing according to the instructions of the MiSeq Reagent
Kit v3 (Illumina, San Diego, CA). Next-generation sequencing
(NGS)was performed by IlluminaMiSeq (Illumina). FASTQ files
were used in the primary data analysis procedure. Qiagen online
analysis software was applied. Primary analysis included the
trimming of adapters using cutadapt (Marcel Martin, Technical
University, Dortmund, Germany). Reads with ,16 bp insert
sequences or with ,10 bp Unique Molecular Index were dis-
carded. Alignment of reads was performed using bowtie (John
Hopkins University, Baltimore, MD), and miRbase V21 was
used for miRNAs. After DESeq2 normalization (18), secondary
analysis revealed significantly differently expressed miRNAs.
Validation of individual miRNAs
RNAwas reverse-transcribed using the TaqManmicroRNA
Reverse Transcription Kit (Thermo Fisher Scientific) and in-
dividual TaqMan miRNA assays (CN: 4427975; Thermo
Fisher Scientific) for tissue and plasma samples. Selected
miRNAs were hsa-miR-451a (ID: 001141), hsa-miR-486-5p
(ID: 001278), hsa-miR-363-3p (ID: 001271), hsa-miR-150-5p
(ID: 000473), hsa-miR-184 (ID: 000485), hsa-miR-483-5p (ID:
002338), hsa-miR-483-3p (ID: 002339), and hsa-miR-183-5p
(ID: 002269). The internal control was RNU48 (ID: 001006)
for tissue samples and cel-miR-39 (ID: 000200) for plasma
samples. Quantitative real-time PCR was performed by the
TaqMan Fast Universal PCR Master Mix (2x) (CN: 4352042;
Thermo Fisher Scientific) on a Quantstudio 7 Flex Real-Time
PCR System (Thermo Fisher Scientific) according to the man-
ufacturer’s protocol for TaqMan miRNA assays with minor
modifications. Negative control reactions contained no cDNA
templates. Samples were always run in triplicate. For data
evaluation, we used the dCt method (delta Ct value equals
target miRNA’s Ct minus internal control miRNA’s Ct) using
Microsoft Excel 2016 (Microsoft, Redmond, WA).
Statistical analysis
Statistical power analysis was performed with a statistical
power and sample size calculator (Tempest Technologies,
Helena, MT). Real-time quantitative PCR data were analyzed
by GraphPad Prism 7.00 (GraphPad Software, La Jolla, CA).
For differentiating between ACA, ACC, and AML groups,
ANOVA or Kruskal-Wallis test was used according to the result
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1 ACA Discovery FFPE F 55 Nonsecreting 25
2 ACA Discovery FFPE M 62 Nonsecreting 40
3 ACA Discovery FFPE M 44 Cortisol 85
4 ACA Discovery FFPE M 62 Nonsecreting 40
5 ACA Discovery FFPE M 50 Nonsecreting 40
6 ACA Discovery FFPE F 57 Nonsecreting 3
7 ACA Discovery FFPE F 64 Nonsecreting 38
8 ACA Discovery FFPE M 55 Nonsecreting 60
9 ACA Discovery FFPE M 44 Cortisol 85
10 ACA Discovery FFPE F 36 Aldosterone 30
11 ACC Discovery FFPE F 70 Nonsecreting 120 ,20 ND 4
12 ACC Discovery FFPE M 43 Nonsecreting 120 ND 6 4
13 ACC Discovery FFPE F 39 Cortisol 90 10 7 2
14 ACC Discovery FFPE F 58 Nonsecreting 115 ND ND 2
15 ACC Discovery FFPE F 53 Aldosterone, cortisol 90 40–50 6 2
16 ACC Discovery FFPE F 72 Nonsecreting 10 4–5 ND 3
17 ACC Discovery FFPE F 46 Nonsecreting 200 42 7 4
18 ACC Discovery FFPE F 50 Nonsecreting ND ND 5 2
19 ACC Discovery FFPE F 54 Nonsecreting 70 20 3 4
20 ACC Discovery FFPE F 55 Nonsecreting 60 20–30 5 4
21 AML Discovery FFPE M 68 Nonsecreting 80
22 AML Discovery FFPE F 66 Nonsecreting 70
23 AML Discovery FFPE F 66 Nonsecreting 35
24 AML Discovery FFPE F 35 Nonsecreting 60
25 AML Discovery FFPE F 55 Nonsecreting 60
26 AML Discovery FFPE F 58 Nonsecreting 80
27 AML Discovery FFPE M 70 Nonsecreting 90
28 AML Discovery FFPE F 37 Nonsecreting 80
29 AML Discovery FFPE M 42 Nonsecreting 80
30 AML Discovery FFPE M 61 Nonsecreting 50
31 ACA Validation FFPE F 55 Nonsecreting 90
32 ACA Validation FFPE M 60 Nonsecreting 30
33 ACA Validation FFPE F 52 Aldosterone 20
34 ACA Validation FFPE M 59 Nonsecreting 35
35 ACA Validation FFPE F 41 Aldosterone 30
36 ACA Validation FFPE M 51 Aldosterone 45
37 ACA Validation FFPE F 48 Aldosterone 10
38 ACA Validation FFPE F 68 Aldosterone 20
39 ACA Validation FFPE F 43 Aldosterone 15
40 ACA Validation FFPE F 84 Nonsecreting 90
41 ACA Validation FFPE F 58 Nonsecreting 40
42 ACA Validation FFPE F 56 Cortisol 25
43 ACA Validation FFPE M 25 Nonsecreting 70
44 ACA Validation FFPE M 64 Nonsecreting 100
45 ACC Validation FFPE F 57 Nonsecreting 60 20–30 5 4
46 ACC Validation FFPE F 62 Cortisol 78 5 5 2
47 ACC Validation FFPE F 61 Nonsecreting 100 20 5 4
48 ACC Validation FFPE F 48 Nonsecreting 120 30 6 4
49 ACC Validation FFPE F 69 Nonsecreting 110 10–20 6 3
50 ACC Validation FFPE M 25 Cortisol 120 10 6 4
51 ACC Validation FFPE M 79 Nonsecreting 86 10 5 3
52 ACC Validation FFPE F 71 Nonsecreting 80 ND ND 4
53 ACC Validation FFPE M 17 Nonsecreting 110 10–15 3 2
54 ACC Validation FFPE F 61 Cortisol 80 20–30 5 4
55 ACC Validation FFPE M 28 Nonsecreting ND ND ND 4
56 ACC Validation FFPE F 47 Nonsecreting 140 20–25 4 4
57 AML Validation FFPE F 36 Nonsecreting 100
58 AML Validation FFPE F 55 Nonsecreting 135
59 AML Validation FFPE M 51 Nonsecreting 30
60 AML Validation FFPE F 62 Nonsecreting 40
61 AML Validation FFPE F 54 Nonsecreting 60
62 AML Validation FFPE F 35 Nonsecreting 50
63 AML Validation FFPE M 46 Nonsecreting 60
64 AML Validation FFPE F 54 Nonsecreting 45
65 AML Validation FFPE F 38 Nonsecreting 110
66 AML Validation FFPE M 60 Nonsecreting 80
67 AML Validation FFPE F 29 Nonsecreting 50
68 AML Validation FFPE F 42 Nonsecreting 110
69 AML Validation FFPE F 44 Nonsecreting 40
70 AML Validation FFPE F 71 Nonsecreting 50
71 AML Validation FFPE M 60 Nonsecreting 45
72 ACA Circulating miRNAs Plasma M 62 Cortisol 40
(Continued)
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of the Shapiro-Wilk normality test. miRNAs that could be used
potentially as minimally invasive biomarkers in adrenal neo-
plasms underwent receiver operating characteristic analysis.
P values ,0.05 were considered significant.
Pathway analysis
The potential targets of miRNAs were investigated using
Diana Tools mirPath v.3 (Diana Lab Tools, University of
Thessaly, Thessaly, Greece). For target prediction, Targetscan
(Whitehead Institute, Cambridge, MA) was used.
Results
miRNA expression profiling by NGS
NGS was performed on 30 FFPE samples. Individu-
al miRNAs are listed in Supplemental Table 1. In total,
256 significantly differentially expressed miRNAs were
found. From the top-ranked overexpressed miRNAs in
AML listed in Supplemental Table 2, we have selected
hsa-miR-451a [fold change (FC) to ACC: 14.7; P ,
0.0001], hsa-miR-486-5p (FC: 14.1; P , 0.0001), hsa-
miR-363-3p (FC: 6; P , 0.0001), and hsa-miR-150-5p
(FC: 6.7; P , 0.0001) to validate. These miRNAs are
significantly upregulated in AML compared with ACA
and ACC. hsa-miR-483-3p (FC: 47.3; P , 0.0001), hsa-
miR-184 (FC: 14.5; P , 0.0001), hsa-miR-483-5p (FC:
18.2; P , 0.0001), and hsa-miR-183-5p (FC: 9.5; P ,
0.0001) were significantly upregulated in ACC compared
with AML and ACA (FC and P values compared with
AML). NGS data are available under the Gene Expres-
sion Omnibus (GEO) accession number GSE112804.
Validation of significantly differentially expressed
miRNAs by real-time quantitative reverse
transcription polymerase chain reaction
In total, 41 independent FFPE samples were subjected
to validation. miRNAs with significantly higher ex-
pression in AML relative to ACA and ACC by NGS were
successfully validated by real-time quantitative reverse
transcription polymerase chain reaction: hsa-miR-451,
hsa-miR-486-5p, hsa-miR-363-3p, and hsa-miR-150-5p
were significantly overexpressed in AML compared with
ACA and ACC (Fig. 1). hsa-miR-363-3p was significantly
overexpressed in AML compared only with ACA, but a
tendency of upregulation can be seen relative to ACC.
However, the validation of significantly overexpressed
miRNAs in ACC compared with AML and ACA by real-
time quantitative PCR was only partly successful, as we
could only observe significant overexpression of three
miRNAs (hsa-miR-184, hsa-miR-483-5p, and hsa-miR-
183-5p) in ACC compared with ACA but not with AML.


















73 ACA Circulating miRNAs Plasma F 37 Cortisol 51
74 ACA Circulating miRNAs Plasma F 77 Nonsecreting 75
75 ACA Circulating miRNAs Plasma M 66 Nonsecreting 50
76 ACA Circulating miRNAs Plasma M 68 Nonsecreting 50
77 ACA Circulating miRNAs Plasma F 69 Nonsecreting 35
78 ACA Circulating miRNAs Plasma F 39 Cortisol 50
79 ACA Circulating miRNAs Plasma F 22 Cortisol 35
80 ACA Circulating miRNAs Plasma F 73 Nonsecreting 45
81 ACA Circulating miRNAs Plasma F 64 Aldosterone 16
82 ACA Circulating miRNAs Plasma M 47 Aldosterone 12
83 ACC Circulating miRNAs Plasma F 36 Cortisol 80 ND ND 4
84 ACC Circulating miRNAs Plasma F 58 Nonsecreting 180 ND 5 4
85 ACC Circulating miRNAs Plasma M 56 Nonsecreting 65 20 5 2
86 ACC Circulating miRNAs Plasma M 39 Cortisol 90 5–10 5 2
87 ACC Circulating miRNAs Plasma M 51 Nonsecreting 170 2 ND 3
88 ACC Circulating miRNAs Plasma M 26 Cortisol 185 10–20 6 3
89 ACC Circulating miRNAs Plasma F 51 Cortisol 10 25 9 3
90 ACC Circulating miRNAs Plasma M 80 Nonsecreting 100 40 10 3
91 ACC Circulating miRNAs Plasma F 56 Testosterone 60 70 6 2
92 ACC Circulating miRNAs Plasma F 62 Testosterone 90 ND 7 3
93 ACC Circulating miRNAs Plasma M 53 Nonsecreting ND ND 10 3
94 AML Circulating miRNAs Plasma F 35 Nonsecreting 100
95 AML Circulating miRNAs Plasma F 59 Nonsecreting 30
96 AML Circulating miRNAs Plasma F 50 Nonsecreting 45
97 AML Circulating miRNAs Plasma F 43 Nonsecreting 95
98 AML Circulating miRNAs Plasma M 39 Nonsecreting 60
99 AML Circulating miRNAs Plasma M 41 Nonsecreting 110
100 AML Circulating miRNAs Plasma M 44 Nonsecreting 100
101 AML Circulating miRNAs Plasma M 49 Nonsecreting 80
102 AML Circulating miRNAs Plasma M 43 Nonsecreting 120
103 AML Circulating miRNAs Plasma M 79 Nonsecreting 97
104 AML Circulating miRNAs Plasma M 42 Nonsecreting 127
Abbreviations: ENSAT, European Network for the Study of Adrenal Tumors; F, female; M, male; ND, no data.
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We have not observed significant differences in the expres-
sion of hsa-miR-483-3p among the groups studied. Most
notably, the expression of hsa-miR-483-5p was similar in
ACC and AML samples. Statistical power analysis showed
that with these 41 samples, the power of our study is.99%.
miRNA expression analysis in plasma samples
Having found significantly differentially expressed
miRNAs in tissue samples, we extended our study to
plasma samples searching for potential minimally
invasive circulating miRNA markers.
Significant overexpression of hsa-miR-
451a and hsa-miR-363-3p in AML
compared with both ACA and ACC
was found (Fig. 2). The expression of
hsa-miR-486-5p and hsa-miR-150-5p
was only significantly upregulated in
AML compared with ACC but not
with ACA.
On the other hand, no significant
differences in the expression of hsa-
miR-184 and hsa-miR-183-5p were
noted. hsa-miR-483-3p and hsa-miR-
483-5pwere significantly overexpressed
in ACC relative to ACA but not to
AML. Statistical power analysis showed
that with the 11 samples per group, the
power of our study is 0.9985.
Diagnostic performance of miRNAs
Circulating miRNAs that could be
potentially used as minimally invasive
biomarkers underwent receiver operating
characteristic analysis. hsa-miR-451a and
hsa-miR-483-3p showed the highest area
under curve (AUC) value. For hsa-miR-
451a, when AML samples were com-
pared with ACA samples, the AUC was
0.88, and when AML samples were
compared with ACC samples, the AUC
valuewas 0.91 (Fig. 3). By selecting 3.676
as the cutoff point, both sensitivity and
specificity were 81.82% for differentiat-
ing AML and ACA. For differentiating
AML and ACC, sensitivity was 90.91%
and specificity was 81.82%by setting the
cutoff point to 3.994. The negative pre-
dictive value of overexpressed hsa-miR-
451a to rule out ACC was 83.33%,
whereas its positive predictive value to
confirm AML was 90%.
Circulating hsa-miR-483-3p per-
formed best in distinguishing ACC
from ACA with an AUC value of 0.88. By setting the
cutoff point to 14.42, sensitivity was 81.82%, whereas
specificity was 90.91%.
Pathway analysis
Among the predicted targets of hsa-miR-451a, hsa-
miR-486-5p, hsa-miR-363-3p, and hsa-miR-150-5p,
mRNAs coding for proteins involved in fatty acid
metabolism, degradation, and biosynthesis were found
(3-oxoacyl-ACP synthase, mitochondrial; enoyl-CoA,
Figure 1. Overexpressed tissue miRNAs in AML and ACC by quantitative reverse
transcription polymerase chain reaction. Mean 6 SD of 2dCt values of selected miRNAs: (a)
hsa-miR-451a, (b) hsa-miR-486-5p, (c) hsa-miR-363-3p, (d) hsa-miR-150-5p, (e) hsa-miR-184,
(f) hsa-miR-483-5p, (g) hsa-miR-483-3p, and (h) hsa-miR-183-5p. **P , 0.01. ***P , 0.001.
****P , 0.0001. ANOVA or Kruskal-Wallis and Tukey or Dunn multiple-comparisons test. Gray
shading represents the candidate miRNA.
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hydratase/3-hydroxyacyl CoA dehydrogenase; cyto-
chrome P450, family 4, subfamily A, member 22).
P value was ,0.0001 for all the three genes (Table 2).
Discussion
Adrenal myelolipoma is an invariably benign tumor, but
it might cause differential diagnostic problems leading to
unnecessary procedures. In our study, we have identified
miRNA markers specific for AML in tissue and plasma
samples. To our knowledge, this is the
first report on the miRNA expres-
sion profile of AML. Based on the
results of NGS, miRNAs hsa-miR-
451a, hsa-miR-486-5p, hsa-miR-363-
3p, and hsa-miR-150-5p performed
best in the diagnosis of AML and were
able to differentiate AML from ACA
and ACC. On the other hand, the al-
ready reportedACC-associatedmiRNAs
hsa-miR-184 (19, 20), hsa-miR-483-5p
(15, 17), and hsa-miR-483-3p were
the most highly ranked overexpressed
miRNAs in ACC. Overexpression of
hsa-miR-183-5p has not yet been re-
ported in ACC and represents a novel
finding, to our knowledge.
Three of four tissue miRNAs were
confirmed by quantitative reverse tran-
scription polymerase chain reaction to
be significantly overexpressed in AML
relative to ACA and ACC (hsa-miR-
451a, hsa-miR-486-5p, and hsa-miR-
150-5p). In concert with previous
findings (16, 21, 22), we have found
that tissue hsa-miR-483-5p was signif-
icantly overexpressed in ACC relative
to ACA, but no difference of expres-
sion relative toAMLhas been observed.
Whereas a tendency of hsa-miR-483-3p
overexpression in ACC was noted,
this has not reached statistical signifi-
cance in our cohort of patients. Over-
expression of both hsa-miR-483-5p and
hsa-miR-483-3p has been previously
described in ACC (23, 24).
Regarding circulating miRNAs,
we demonstrated that hsa-miR-451a
and hsa-miR-363-3pwere significantly
overexpressed in AML relative to ACA
and ACC. In addition, hsa-miR-486-
5p and hsa-miR-150-5p were signifi-
cantly overexpressed in AML but only
compared with ACC and not with ACA. In concordance
to previous studies (13, 15, 17, 20), we have observed a
significant overexpression of plasma hsa-miR-483-5p
and hsa-miR-483-3p in patients with ACCs, but we could
not detect a significant difference of these in expression
between AML and ACC.
Tissue and circulating hsa-miR-483-5p has been
considered the best marker of adrenocortical malignancy
to date (13, 15, 17). The noted lack of significance be-
tween ACC andAML in the expression of both tissue and
Figure 2. Overexpressed circulating plasma miRNAs in AML and ACC by quantitative reverse
transcription polymerase chain reaction. Mean 6 SD of 2dCt values of selected miRNAs: (a)
hsa-miR-451a, (b) hsa-miR-486-5p, (c) hsa-miR-363-3p, (d) hsa-miR-150-5p, (e) hsa-miR-184,
(f) hsa-miR-483-5p, (g) hsa-miR-483-3p, and (h) hsa-miR-183-5p. *P , 0.05. **P , 0.01.
ANOVA or Kruskal-Wallis and Tukey or Dunn multiple-comparisons test. Gray shading
represents the candidate miRNA.
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plasma hsa-miR-483-5p and hsa-miR-483-3p is clinically
relevant because it might represent a limitation in the use
of these markers.
It is intriguing that there has been no significant
difference in the tissue expression of hsa-miR-184,
hsa-miR-483-3p, hsa-miR-483-5p, and hsa-miR-183-5p
between ACC and AML, whereas three of these four
miRNAs were significantly overexpressed in ACC vs
ACA. Although it is pure hypothesis at present, the
similar miRNA expression between ACC and AML
might indicate some common step in their pathogenesis.
Pathway analysis revealed that the significantly overex-
pressed miRNAs of AML are mostly linked to fatty acid
metabolism. The miRNAs overexpressed in AML have
been reported to be involved in several tumors. hsa-miR-
451a was reported to be overexpressed in pancreatic
ductal adenocarcinoma (25) and papillary thyroid car-
cinoma (26) but downregulated in lung adenocarci-
noma (27) and melanoma (28). According to the cellular
context, the same miRNA can behave as an overex-
pressed oncogene or downregulated tumor suppressor in
different tissues (14). hsa-miR-486-5p is mostly down-
regulated in different tumors and classified as a tumor
suppressor (29, 30). Both hsa-miR-363-3p (31, 32) and
hsa-miR-150-5p (33, 34) are mostly downregulated in
various tumors. It seems that the overexpressed miRNAs
in AML are mostly downregulated in other tumors. AML
might thus represent a unique tissue
context. Red blood cells are known to
harbor hsa-miR-451 and hsa-miR-486-
5p (35); moreover, hsa-miR-451 seems
to be involved in erythropoiesis (36).
hsa-miR-451 and hsa-miR-486-5p are
among the most abundant miRNAs
in the blood of healthy individuals
(37), and their overexpression in AML
might thus be related to the presence of
extramedullary hematopoiesis.hsa-miR-
363 that was found to be overexpressed
in our AML samples was associated
with the regulation of adipogenesis (38).
Tissue and plasma miRNAs are not always parallel. In
ACC, for example, tissue hsa-miR-34a was down-
regulated but upregulated in serum samples (15). In
another report on endometrioid endometrial carcinoma,
the expression of hsa-miR-9 and hsa-miR-301b was
differentially expressed in the tissue and in blood (39).
Unfortunately, the mechanisms for active miRNA release
to body fluids are incompletely understood, and most
notably, the processes for miRNA sorting in the extra-
cellular vesicles await clarification (40).
Circulating miRNA markers of AML might be of
diagnostic relevance if applied presurgically. Among the
miRNAs analyzed, hsa-miR-451a appears to be the best
candidate for validation studies and possible subsequent
integration into clinical practice.
Because ACC is a rare tumor and AML is mostly left
nonoperated, the collection of sufficient numbers of
preoperative plasma samples from patients with histo-
logically proven tumors is difficult. Whereas wemanaged
to include 25 AML FFPE samples for tissue miRNA
analysis, only 11 AML samples for circulating miRNA
were available, which is certainly a limitation of this
study. Statistical power analysis, however, revealed that
the power of our analysis for FFPE and plasma miRNAs
has been .99%.
In this study, we have included only samples from
patients with a histological diagnosis of adrenal tumors.
Figure 3. Evaluation of the diagnostic applicability of hsa-miR-451a by receiver operating
characteristic (ROC) curves. ROC curve of hsa-miR-451a in AML compared with ACA and
ACC: (a) AML compared with ACA and (b) AML compared with ACC.
Table 2. Results of the Pathway Analysis for miRNA Overexpressed in AML
KEGG Pathway P Value Gene
Fatty acid metabolism (hsa01212) ,0.0001 OXSM, EHHADH
Fatty acid degradation (hsa00071) ,0.0001 CYP4A22, EHHADH
GABAergic synapse (hsa04727) ,0.0001 SLC38A1, GABRB3, NSF, GABRA4, SLC12A5
Fatty acid biosynthesis (hsa00061) ,0.0001 OXSM
Vitamin B6 metabolism (hsa00750) ,0.001 PNPO
Abbreviations: CYP4A22, cytochrome P450, family 4, subfamily A, member 22; EHHADH, enoyl-CoA and 3-hydroxyacyl CoA dehydrogenase; GABA,
g-aminobutyric acid; GABRA4, g-aminobutyric acid type A receptor a4 subunit; GABRB3, g-aminobutyric acid type A receptor b3 subunit; KEGG, Kyoto
Encyclopedia of Genes and Ganomes; NSF, N-ethylmaleimide sensitive factor, vesicle fusing ATPase; OXSM, 3-oxoacyl-ACP synthase, mitochondrial;
PNPO, pyridoxamine 50-phosphate oxidase; SLC12A5, solute carrier, family 12, member 5; SLC38A1, solute carrier, family 38, member 1.
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However, if the inclusion criteria are less stringent (i.e.,
plasma samples from patients having AML based on
unambiguous imaging diagnosis can be included), the
cohorts can be increased considerably. Such a prospective
study can be proposed in the future to confirm the utility
of AML-associated circulating miRNA markers (mostly
circulating hsa-miR-451a) as a minimally invasive bio-
marker. The negative predictive value of overexpressed
circulating hsa-miR-451a to rule out ACC is not high
for clinical introduction at present, but this might be
improved by sample size extension in such a further
prospective study. Such a marker might be helpful for
confirming patients with large tumors to have AML and
thus might help to avoid unnecessary surgery.
In conclusion, to our knowledge, we have performed
the first miRNA profiling of adrenal myelolipoma and
identified miRNAs that are significantly differentially
expressed between AML and adrenocortical benign and
malignant tumors. Circulating miRNA markers could
potentially serve as noninvasive diagnostic biomarkers,
but further studies on larger cohorts are needed to
confirm their clinical usefulness and applicability.
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